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The central nervous system complications
of bone marrow transplantation in children
Abstract Bone marrow transplanta-
tion (BMT) is widely performed for
both neoplastic and non-neoplastic
disease. Before BMT, patients are
prepared with high-dose chemo-
therapy, frequently associated with
total-body radiation, to destroy
residual malignant cells and to reduce
immunologic resistance. BMT is
associated with several central ner-
vous system (CNS) complications
secondary to underlying disease, pro-
longed myelosuppression, and the use
of immunosuppressive drugs. These
complications include infections,
vascular disease, drug-induced neuro-
toxicity, metabolic disturbance, and
post-BMT carcinogenesis. The
immune status of children after BMT
can be divided into three phases: the
pre-engraftment period (days 0–30
after BMT), the post-engraftment
period (days 30–100), and the late
phase (after day 100). The timing of
CNS complications that occur after
BMT, as for complications in other
organs, can be described with refer-
ence to these three phases of immune
status. It is essential that radiologists
become familiar with the relationships
between the immune status of the
recipient and the times of onset of
these disorders, and with the neuro-
imaging patterns associated with the
various complications. CNS compli-
cations can be life-threatening for
immunosuppressed children, so accu-
rate diagnosis is important for prompt
and appropriate treatment.
Keywords Bone marrow
transplantation . Central nervous
system . Immunosuppression .
Pediatrics
Introduction
Bone marrow transplantation (BMT) is performed for the
treatment of pediatric patients with hematologic malig-
nancies (leukemia, malignant lymphoma), solid neo-
plasms, bone marrow aplasia, and a variety of congenital
dyshematopoietic and metabolic diseases [1–3]. The par-
ticular approaches used have a variety of names depending
on the relationship between the marrow donor and the
recipient and on the source of the blood stem cell (Table 1)
[1–3]. In this review we consider all types of donors and
recipients and use bone marrow transplantation (BMT) as
an inclusive term.
Before BMT, the patient is prepared with high doses of
chemotherapy, frequently associated with total-body irra-
diation, to destroy the hematopoietic system and to
suppress the immune system, especially T-cells, so that
graft rejection is prevented. In patients with malignancies,
the preparative regimen also serves to reduce the tumor
burden. These preparative therapies can predispose patients
to infection, thrombocytopenia, metabolic disturbance, and
potential neurotoxicity, including impaired development
of the nervous system. Among these complications, the
frequency of central nervous system (CNS) involvement
associated with BMT is reported to be 11–65% (90% at
autopsy) of BMT recipients, and these CNS complications














may be the main causes of death in 9–17% [4–10]. To
begin proper treatment as early as possible, accurate
diagnosis is important and imaging [magnetic resonance
imaging (MRI) and computed tomography (CT)] is helpful
for diagnosis.
In this paper, we review the characteristic imaging
findings and appearances of CNS complications associated
with BMT in children and correlate these complications
with clinical background according to the time elapsed
after BMT.
Immune status following BMT
BMT recipients experience a transient, but profound state
of immune deficiency. The immune status of children after
BMT can be divided into three phases: the pre-engraftment
period (phase I, days 0–30 after BMT), the post-
engraftment period (phase II, days 30–100), and the late
phase (phase III, after day 100) (Table 2) [1, 9, 11]. During
phase I, the pre-engraftment period (<day 30), the immune
system of patients is completely suppressed and the
hemopoietic system is destroyed as a result of the
preparative conditioning regimen for BMT, which involves
high-dose chemotherapy often associated with irradiation.
Pancytopenia may occur, especially associated with severe
neutropenia (less than 100/μl), causing a high risk of
infection. In the next phase, the post-engraftment period
(days 30–100), engraftment of donor marrow is confirmed,
and immune recovery starts, although immune depletion
(cellular immunodeficiency) continues. Acute graft versus
host disease (GVHD) may develop, caused by alloreactive
donor-derived T-cells in the graft attacking nonshared
recipient antigens in target tissues (skin, liver, and intestinal
tract), resulting in erythematous maculopapular rash,
persistent anorexia, vomiting and/or diarrhea, and liver
dysfunction. The high dose of chemotherapy associated
with irradiation during the conditioning regimen before
BMT can cause damage in host tissues including the
mucosa, liver, and other tissues. Activated cells from
damaged recipient tissues secrete many inflammatory
cytokines, such as interleukin-1 (IL-1), tumor necrosis
factor (TNF)-alpha, granulocyte-macrophage colony-sti-
mulating factor (GM-CSF), and interferon (IFN)-gamma,
which may upregulate expression of recipient antigens.
After BMT (commonly during phase II, days 30–100),
presentation of recipient antigens to donor T cells occurs,
and subsequent proliferation and differentiation of these
activated T cells is crucial in this phase of GVHD.
Activated CD4+ T-cells (helper T cells) expand and
generate cytokines such as tumor necrosis factor (TNF)-
alpha, interleukin-2, and interferon-gamma. These cyto-
kines cause tissue damage and promote differentiation of
CD8+ T-cells to cytotoxic T-cells, which kill recipient cells
Table 2 Immune status after
BMT




HLA: human leukocyte antigen
Auto-: autologous,
allo-: allogenic
PBSCT: peripheral blood stem
cell transplantation
CBSCT: cord blood stem cell
transplantation
Source Donor Full name
Bone marrow Identical twins Syngenetic BMT
HLA-matched relation Related allo-BMT
HLA-matched unrelated individual Unrelated allo-BMT
Same individual Auto-BMT
Peripheral blood stem cell Same individual Auto-PBSCT
HLA-matched relation Related allo-PBSCT
HLA-matched unrelated individual Unrelated allo-PBSCT
Cord blood stem cell HLA-matched relation Related allo-CBSCT
HLA-matched unrelated individual Unrelated allo-CBSCT
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and further disrupt tissues. The prophylaxis of GVHD
mainly consists of post-transplant administration of immu-
nosuppressive drugs such as cyclosporine or tacrolimus,
with methotrexate, steroids, anti T-cell antibodies, and
other immunosuppressive agents. These GVHD prophy-
laxes can impair post-transplant immunologic reconstitu-
tion. After about 100 days (late phase), immune recovery
occurs progressively towards complete recovery. Chronic
GVHD may develop and is the most frequent late
complication. In chronic GVHD, patients with only liver
and skin involvement have a favorable prognosis. By
comparison, patients with chronic GVHD and extensive
involvement of multiple organ systems may experience
prolonged cellular and humoral immunosuppression asso-
ciated with the immunosuppressive regimens necessary to
control GVHD, and the prognosis may be poor. Graft
failure or relapse of underlying disease can occur during
this phase [1, 11].
The timing of CNS complications that occur after
transplantation is similar to the timing of complications in
other organs and can be described with reference to the
three phases of recipient immune status (Table 3) [1, 2, 11,
12]. It is very important for radiologists to appreciate how
the different timing of onset of complications and their
neuroimaging patterns can vary according to the immune
status of the patient. Infections, vascular disease, drug-
induced neurotoxicity, metabolic disturbance, and post-
BMT carcinogenesis are the important CNS complications
after BMT in children.
Infectious disease
Infectious disease is the most common CNS complication
of BMT (2.2–14%) and one of the most common causes of
morbidity after BMT, although the incidence has reduced
recently. Susceptibility to different infectious agents varies
with the nature of immune impairment after BMT [4–13].
During the first phase (<day 30), there is a particularly
high risk of certain fungal infections (Aspergillus, Candi-
da), gram-negative bacterial infections and viral infections,
although prophylactic antibiotic or antifungal treatment is
commonly a component of conditioning regimens (Fig. 1).
During the second period (days 30–100), which is
characterized by profound deficiency of cellular immunity,
GVHD is itself an additional risk factor for fungal and viral
opportunistic infections, as are the immunosuppressive
agents. CNS involvement is predominantly with virus
(human herpesvirus-6, cytomegalovirus), fungi, Toxoplas-
ma, and gram-positive bacteria. In the late phase (>day
100), infections caused by encapsulated bacteria and
herpes zoster virus are commonly seen, and progressive
multifocal leukoencephalopathy (PML) may rarely occur
[11].
Aspergillosis
Aspergillosis is the most common CNS infection after
BMT, especially during the first and second periods. In
Table 3 CNS complications
after BMT
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most cases, invasive aspergillosis develops in the paranasal
sinuses and in the lungs, and spreads secondarily to the
brain. Involvement of the spinal cord is very rare. The
mortality rate for cerebral aspergillosis approaches 85–
100%, depending on the degree of neurological compro-
mise at presentation [14–15]. Presenting symptoms are
nonspecific (stroke-like symptoms or seizures), and fever
may be absent. The organism is rarely cultured from
cerebrospinal fluid, so the clinical diagnosis of cerebral
aspergillosis can be difficult.
Imaging findings Vasculopathy and secondary multiple
septic infarcts occur, involving the lenticulostriate and
thalamoperforating artery distributions, often associated
with hemorrhage and abscess formation. Involvements of
basal ganglia, thalami, and the corticomedullary area are
common. Brain-computed tomography (CT) shows mul-
tiple irregular, low attenuated areas with little enhance-
ment after administration of intravenous contrast medium,
often associated with high attenuation due to hemorrhage
(Fig. 2). Magnetic resonance imaging (MRI) detects many
more lesions than CT. On T2-weighted image (T2WI),
intermediate-low intensity within a surrounding high
signal area can be seen. Diffusion-weighted images are
useful for early detection of multiple septic infarcts. Ring-
like enhancement is often absent, reflecting the deficiency
of inflammatory response caused by the severely im-
munosuppressed status. In a less severely immunocom-
promised status, there may be ring-like enhancement.
T2WI and FLAIR images are also useful for detection of
Fig. 1 A 17-year-old boy after BMT 4 years ago due to hepatic
undifferentiated sarcoma presented with acute myeloblastic leuke-
mia. Chemotherapy with PBSC rescue was performed. The next day,
he had fever, cognitive and memory disturbance, and ataxia. Axial
FLAIR magnetic resonance (MR) image shows abnormal hyper-
intense signal in the left temporal lobe with multiple spotty
hyperintense lesions dominantly in subcortical white matter (not
shown). (a) Post-contrast T1-weighted axial image shows the lesion
enhanced and partially ring-like enhanced in the left temporal lobe
(arrowhead). (b) Axial diffusion-weighted image and ADC map (not
shown) reveal diffusion restriction of the lesion in the left temporal
lobe (arrowhead). Fungal infection with microabscess formation was
suspected. Antifungal therapy was performed, and his neurological
symptoms improved and the abnormal small nodules with
microabscesses disappeared
Fig. 2 A 25-year-old man after BMT because of Hodgkin disease
and secondary acute myeloid leukemia, complicated by acute
GVHD. He experienced sudden onset of left pupil dilatation and left
hemiparesis. Plain axial CT images revealed a low-attenuated lesion
in the right internal capsule and right frontal lobe, associated with
hemorrhage (not shown). Follow-up CT obtained 2 days later
showed hemorrhage of the midbrain lesion with perforation to the
third ventricle. The patient died 8 h after the second CT study.
Autopsy revealed evidence of systemic aspergillosis (courtesy of Dr.
K. Yamada, Kyoto Prefectural University of Medicine)
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additional lesions containing hyphae without an inflam-
matory reaction in an immunocompromised host; these
appear as small, subcortical hyperintense lesions in the
subcortical area with no contrast enhancement [14–17].
Human herpes virus-6 (HHV-6) encephalitis
In most children, primary HHV-6 infection occurs between
6 months and 5 years of age [1, 18, 19]. After the primary
infection, HHV-6 probably remains latent in the body and
then reactivates upon host immunosuppression, similarly to
other human herpes viruses. Systemic reactivation of HHV-
6 develops in 28–78% of BMT recipients, usually in the
first or second phase after BMT, and is associated with
acute GVHD, although encephalitis occurs in only a
minority [18–19]. Because of premedication with acyclovir
or gancyclovir, cytomegalovirus (CMV), herpes simplex
virus (HSV), and herpes zoster virus (HZV) infections are
less common, although gancyclovir may cause leukopenia
and T-cell immune suppression. The clinical symptoms of
HHV-6 encephalitis are anterograde amnesia, change in
mental state, headache, fever, and drowsiness. Polymerase
chain reaction (PCR) detection of HHV-6 DNA in the
cerebrospinal fluid in association with CNS symptoms has
been shown to have a high sensitivity. The outcome may
vary from near complete recovery to death, and the
mortality is more than 50%, although prompt treatment
with foscarnet is dramatically effective [18–19].
Imaging findings Characteristic involvement of the limbic
system is typical, including the medial temporal lobes,
hippocampi, insula, subfrontal and cingulate gyri. Lesions
are often hemorrhagic. CT findings in patients with HHV-
6 encephalitis are usually negative. MRI can also be
normal in the first few days. Thereafter, T1 and T2
prolongation in the grey and subcortical white matter of
the bilateral limbic systems can be detected, with contrast
enhancement. Axial and coronal T2WI and FLAIR images
have high sensitivity in the early detection of HHV-6
encephalitis as symmetrical abnormal hyperintensity in the
limbic system. On diffusion-weighted images, these
lesions are shown as symmetrical hyperintensity with a
low apparent diffusion coefficient (ADC) in the early stage
[18–21] (Fig. 3)
Bacterial infection
In the second phase (days 30–100), gram-positive bacterial
infections are predominant, although they have decreased
in frequency because of prophylactic usage of antibiotics
[1, 11, 12]. Methicillin-resistant Staphylococcus aureus
(MRSA), methicillin-resistant Staphylococcus epidermidis
(MRSE), and Listeria monocytogenes may cause severe
meningitis, encephalitis, and ventriculitis. The clinical
symptoms are nonspecific: fever, headache, drowsiness,
and seizures.
Imaging findings Lesions are more commonly detected
with MRI than CT. In meningitis, abnormal thickening and
enhancement of the leptomeninges are detectable on MRI
with contrast enhancement. In pyogenic ventriculitis,
hydrocephalus and abnormal enhancement of the ventric-
ular lining with diffusion restriction are typical findings on
MRI, with intraventricular debris and pus deposition, and
occasionally abnormal thickening and enhancement of the
choroid plexus (Fig. 4). Diffusion-weighted image (DWI)
has higher sensitivity than any other sequence for
detection of intraventricular and periventricular signal
abnormality [22–25].
Progressive multifocal leukoencephalopathy (PML)
During the late phase (>day 100) after BMT, reactivation of
the JC virus may develop in 10–15% of recipients with
asymptomatic viruria. JC virus is tropic for renal epithe-
Fig. 3 A 22-year-old boy after
BMT (day 19) due to non-
Hodgkin lymphoma associated
with Langerhans cell histiocy-
tosis. He experienced sudden
onset of anterograde amnesia
and seizure. a Coronal FLAIR
image performed after 2 days
shows hyperintense lesion in the
medial temporal lobe clearly. b
On axial diffusion-weighted
image, bilateral medial temporal
lobe is detected as symmetrical
hyperintense lesion. HHV-6
DNA was detected in the CSF
by using quantitative PCR
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lium and may infect oligodendrocytes in the brain, and is
thus the etiologic agent of PML [1]. Pathologic features are
multifocal demyelination with intranuclear inclusion bod-
ies in oligodendrocytes. Unlike HIV infection or other
organ transplantation, BMT rarely causes PML (only eight
adult cases have been reported), and we could not find any
report of pediatric PML after BMT. In adults, slowly
progressive mental deterioration, sensory deficits, paraly-
sis, ataxia, and visual disturbance are the clinical symptoms
[17, 26].
Imaging findings Imaging findings of PML are similar in
children and adults. On CT, multiple areas of decreased
attenuation are typical. MRI shows multiple subcortical
white matter lesions with T1 and T2 prolongation in the
frontal and parieto-occipital regions (Fig. 5). The lesions
lack mass effect and do not enhance with contrast material
[17, 26].
Vascular disease
Cerebrovascular disease occurs in 3.8–8.8% of BMT
recipients (more than 50% at autopsy), mostly during the
first or second phases after BMT [4–9]. Subdural hemor-
rhage is most common, reflecting thrombocytopenia.
Intraparenchymal hemorrhage, subarachnoid hemorrhage,
and infarction may also develop (Fig. 6). Thrombotic
Fig. 4 A 3-year-old boy after BMT (day 77) because of
myelodysplastic syndrome, complicated by GVHD. He had a
fever and presented with a stiff neck. MRI was performed on day 78
after BMT. a Axial T2-weighted MR image shows ventriculomegaly
with periventricular hyperintensity. Atrophy and hyperintensity of
the white matter are also seen due to drug-induced neurotoxicity. b
Axial diffusion-weighted image and ADC map (not shown) reveal
the periventricular lesion with diffusion restriction. MRSA was
detected in the cultured CSF
Fig. 5 Adult case of progres-
sive multifocal leukoencepha-
lopathy (PML). A 66-year-old
woman treated for AML. a
Axial T2-weighted MR image
shows multiple diffuse or patchy
lesions predominantly in the
bilateral subcortical white matter
presenting T2 prolongation. b
On T2-weighted midsagittal MR
image, involvement of the cor-
pus callosum can be seen
(courtesy of Dr. H. Tanaka,
Osaka University)
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diseases are reported to be associated with endocarditis,
indwelling catheter, and characteristically with treatment
with L-asparaginase in ALL children [27–28]. During the
second and late phases, CNS angiitis can occur with
GVHD [29].
Drug-induced neurotoxicity
During the pre-transplantation period, high doses of
chemotherapy, frequently associated with total-body irra-
diation, are administered to destroy residual malignant cells
and to reduce immunologic resistance. In the post-trans-
plantation period, immunosuppressive drugs such as
methotrexate, cyclosporine, tacrolimus, and steroids are
administrated as prophylaxes against GVHD. These drugs,
with or without irradiation, can themselves induce CNS
complications that may be life-threatening. MRI is
generally the optimal imaging investigation in the follow-
up. OnMRI, drug-induced neurotoxicity generally presents
with high signal intensity on T2WI and FLAIR and low
signal intensity on T1WI, reflecting impairment of the
blood-brain barrier due to endothelial damage and
vasogenic edema, demyelination, gliosis, ischemia, and
tissue necrosis [30].
From the time of prophylactic chemotherapy before
BMT to a few weeks after BMT (first phase), an acute post-
therapy syndrome may occur, commonly presenting as
vasogenic edema resulting from damage to the capillary
endothelium. From a few weeks to a few months after
BMT, an early delayed reaction may develop, including
demyelination, astrogliosis, multifocal coagulative necro-
sis, and cavitation, transient in many cases. Disseminated
necrotizing leukoencephalopathy has a poor neurological
prognosis. During the late phase, from several months to
several years after BMT, a late delayed reaction develops
that reflects vascular changes with secondary ischemic
changes causing tissue damage. Damage to the endothe-
lium may lead to change in the vessel wall (e.g., resulting in
moyamoya-like collaterals) [30].
Posterior reversible encephalopathy syndrome (PRES)
Immunosuppressive medications, such as cyclosporine-A,
tacrolimus, and steroids, can induce PRES. The mechanism
is still unclear, although the immunosuppressive drug itself
may disrupt the blood-brain barrier or interfere with
cerebrovascular autoregulation, resulting in vasogenic
edema. PRES can potentially progress to irreversible
cytotoxic edema [31–33].
Commonly, within 1 month of the beginning of prophy-
lactic treatment (first and second phases), a usually revers-
ible neurogenic syndrome develops with headache, altered
mental status, seizures, and loss of vision or consciousness.
The immunosuppressive and/or chemotherapeutic drugs
causing PRES should be discontinued or switched. Once
treatment is stopped, further deterioration may occur for 1 or
2 weeks before improvement. Treatment of hypertension, if
any, is needed. Complete disappearance of clinical and
imaging findings may occur, but residual sequelae are not
rare [31–35].
Imaging findings CT shows hypodense lesions predomi-
nantly in the parieto-occipital regions. However, MRI is
more sensitive than CT, and FLAIR appears to be the most
sensitive pulse sequence. Typically, FLAIR images
demonstrate hyperintensity in the parieto-occipital and
posterior frontal cortical and subcortical white matter
(Fig. 7). Less commonly, the brainstem, basal ganglia, and
cerebellum are involved (Fig. 8). In general, the lesions are
symmetric, but asymmetrical presentations are not rare.
The brainstem and deep white matter lesions may tend to
be irreversible. Atypical imaging findings include contrast
enhancement, hemorrhage, and restricted diffusion on
MRI, which are correlated with the extent of hyperinten-
sity and mass effect on FLAIR [31–34].
Methotrexate (MTX)-induced leukoencephalopathy
Prophylactic chemotherapy using methotrexate can cause
leukoencephalopathy. The dose of intravenous (not intra-
thecal) MTX correlates with the incidence of leukoen-
cephalopathy, regardless of history of radiation therapy.
The prevalence of leukoencephalopathy is reported to be
Fig. 6 A 3-year-old boy after BMT (day 87) for myelodysplastic
syndrome. He was treated with immunosuppressive drugs and
transfusion for GVHD and severe pancytopenia due to dyshemato-
poiesis. A plain axial CT scan reveals a low density lesion in the
right cerebellar hemisphere (not shown). Axial diffusion-weighted
image performed on the same day shows marked diffusion
restriction in the right cerebellar lesion. Subacute cerebellar
infarction was diagnosed
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from 16 to 69%. Neurological symptoms may or may not
be present, and the neurological outcome is good in many
cases. Typically, patients have neurological symptoms
when an injury occurs acutely. This is not the precursor of
disseminated necrotizing leukoencephalopathy [30, 35, 36].
Imaging findings MRI is more sensitive than CT for
detection of lesions. MRI shows bilateral high signal
intensity, primarily in central and periventricular white
matter on T2WI and FLAIR, with or without diffusion
restriction (Fig. 9). Subcortical white matter is relatively
spared. The corpus callosum, hippocampal commissure,
and anterior commissure are most often spared. The
lesions are transient, but may remain visible for a long
time after the disappearance of clinical symptoms. If foci
of contrast enhancement and of T1 and T2 shortening are
seen, the development of diffuse necrotizing leukoenceph-
alopathy should be considered (see next section) [17, 30].
Disseminated necrotizing leukoencephalopathy (DNL)
Diffuse white matter injury after intrathecal administration
of methotrexate with or without cranial radiotherapy is a
not infrequent CNS complication. Rapidly progressive
deterioration occurs clinically, presenting with drowsiness,
confusion, seizure, ataxia, and dementia resulting in poor
neurological outcome. This form of leukoencephalopathy
is differentiated from other forms, such as PRES and
MTX-induced leukoencephalopathy, by the presence of
more extensive areas of white matter necrosis in DNL [17,
36, 37].
Imaging findings On MRI, progressive signal changes
with mass effects in deep white matter represent diffuse
Fig. 8 A 5-year-old girl after BMT (day 25) because of Fanconi
anemia who presented with a seizure. She was being treated with
tacrolimus for GVHD. Axial FLAIR MR image shows pathy
hyperintense lesions in the bilateral cerebellar hemisphere and left
parieto-occipital lobe. The cortical-subcortical lesions predomi-
nantly in the parieto-occipital lobe are consistent with PRES. The
cerebellar involvement as in this case is rarely seen
Fig. 7 A 7-year-old girl after BMT (day 62) for chronic EV virus
infection and treated with cyclosporine A, presenting with a sudden
seizure. Axial FLAIR MR image shows cortical-subcortical abnor-
mal hyperintense lesions in the bilateral parieto-occipital lobes.
These imaging appearances are typically consistent with PRES
Fig. 9 An 8-year-old boy after BMT because of non-Hodgkin
lymphoma. Before BMT, MTX/hydrocortisone therapy was per-
formed. Axial FLAIR MR image demonstrates hyperintense
changes in the bilateral deep white matter without T2 shortening
foci. The cerebral atrophy is thought to be due to the chemotherapy
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necrotizing foci as T1- and T2-shortening lesions
(Fig. 10). Injury to the blood-brain barrier results in
marked contrast enhancement with irregular ring-like
shapes. Later, calcifications may be seen on CT if the
patients survive [17, 36, 37].
Metabolic disturbance following BMT
Metabolic disturbances involving the CNS are less frequent
than other CNS complications after BMT, but may be life-
threatening occasionally. They usually develop during the
first to second phase after BMT and may result from renal
failure, hepatic failure, electrolyte imbalance, and hypoxia
[4]. Among the CNS complications following BMT,
Wernicke’s encephalopathy has been reported in 5.5% at
autopsy [8]. Central pontine myelinolysis may also
develop, but is very rare [39].
Children given BMT before puberty may later develop
growth impairment caused by prophylactic chemotherapy
with or without irradiation therapy. Injury to the hypotha-
lamic-pituitary axis leads to inappropriately low production
of growth hormone. Annual growth evaluation should be
performed in all children after BMT. Less frequently,
delayed puberty and deficiency of secondary sex characters
can develop [1].
Central pontine myelinolysis
Central pontine myelinolysis is a rare CNS complication
after BMT, being more common following liver trans-
plantation (29% at autopsy after liver transplantation)
[39]. It is a demyelinating disorder affecting mainly the
central part of the pons, accompanied by extrapontine
myelinolysis in some cases. Demyelination is thought to
be related to cellular (and/or vasogenic) edema, caused by
hyponatremia especially in the case of rapid correction or
associated with hypoxia. Patients deteriorate subacutely
(usually within a few days) to coma, quadriplegia,
pseudobulbar palsy, and extrapyramidal motor symptoms
[17, 30].
Imaging findings CT and MRI show a symmetrical lesion
with a typical “ω” or “batwing” shape in the center in the
pons (hypoattenuation on CT and T2-prolongation on
MRI). MR images (especially T2WI) have higher sensi-
tivity than CT. Corticospinal tracts may be spared.
Restriction of diffusion occurs in the subacute phase
(within a few days). Extrapontine involvement including
the thalamus, basal ganglia, and cerebellum may be
observed [30].
Post-BMT carcinogenesis
Post-transplantation lymphoproliferative disorder (PTLD),
therapy-induced neoplasm, and CNS relapse can appear in
the late phase after BMT. PTLD following BMT in children
is a rare, but life-threatening complication. On the other
hand, the overall risk of developing secondary brain tumors
is significantly higher after BMT than in the general
population. Radiation-induced telangiectases and second-
ary neoplasms such as glioblastoma multiforme and
meningioma are well known. CNS relapse may also
occur (Fig. 11).
Fig. 10 A 16-year-old boy with ALL after prophylactic therapy
using intrathecal high-dose MTX therapy before BMT. He presented
with seizure, confusion, and drowsiness. a On axial T1-weighted
MR image, irregular T1-shortening areas with widespread surround-
ing edema can be detected. b Axial T2-weighted image shows the
necrotizing foci as T2-shortening area with edema diagnosed as
disseminated necrotizing leukoencephalopathy (DNL). His neuro-
logical symptoms deteriorated, and BMT had to be abandoned. He




Chronic immunosuppression leads to an unregulated
expansion of lymphoid cells in patients after allogenic
BMT [40–42]. Post-transplantation lymphoproliferative
disorder (PTLD) represents a spectrum of unregulated
lymphoid expansion that ranges from polyclonal B-cell
proliferation to monoclonal malignant lymphoma. PTLD
can occur from about 6 weeks to 7 years after transplan-
tation. In most cases, the disorder results from Epstein-Barr
virus (EBV)-induced B cell proliferation related to
pharmacological suppression of the T cell system. Allo-
graft-type BMT, Epstein-Barr virus infection, and immu-
nosuppression are risk factors increasing the incidence of
PTLD. The incidence of PTLD after BMT is reported to be
0.6–10%, with low frequency in children after autologous
BMT [40, 43, 44]. In children, brain involvement occurs
less commonly, in 1 to 6% of cases among all kinds of
organ transplantation (abdomen 64%, thorax 50%, head
and neck 25%), but CNS involvement is associated with
poor prognosis [41].
Imaging findings CT and MR images are both useful
modalities for detection of lesions. Diffuse cervical
lymphadenopathies, orbital soft tissue mass, and sinonasal
involvement can be observed. In the brain parenchyma,
solitary periventricular-subcortical mass can be seen.
Fig. 12 A 32-year-old man after BMT 6 months ago because of
ALL. He presented with left hemiparesis and fever. a On plain axial
CT, a solitary subcortical high density lesion can be seen. b Axial
T2- and T1- (not shown) weighted MR images depict the
isointensity mass lesion in the right temporal lobe. Diffusion
restriction of the lesion is seen on ADC map (not shown). c Post-
contrast T1-weighted axial image reveals irregular contrast-en-
hanced mass. Initially, brain abscess was suspected, and drainage
was performed; pathology showed this mass to be PTLD (courtesy
of Dr. K. Ichihashi, Kurashiki Central Hospital)
Fig. 11 A 23-year-old boy who
had received BMT 1 year ago
for non-Hodgkin lymphoma
presented with right deviation of
his tongue. a Post-contrast T1-
weighted coronal image shows
an irregular mass-like lesion in
the right skull base along to the
hypoglossal canal with contrast
enhancement. b A post-contrast
T1-weighted sagittal image
shows parietal skull involve-
ment. Multiple vertebral invol-





Intertumoral hemorrhage and necrosis are more frequently
seen in PTLD than in primary CNS lymphoma. CT shows
highly attenuated lesions reflecting hypercellularity or
hemorrhage. MR images can reveal hemorrhage and
necrosis in the mass lesion, with ring-like enhancement
on administration of contrast material (Fig. 12) [41–42].
Since these imaging findings are often non-specific and
the differentiation from the other disease entities is not
straightforward, biopsy is usually required to help to
confirm the diagnosis.
Conclusion
The frequency of various CNS complications after BMT
differs according to the period after BMT. Except for the
detection of hemorrhage or calcification, MRI is generally
the optimal imaging investigation. In particular, T2WI and
FLAIR images are useful because of their higher sensitivity
for detecting white matter lesions compared with other
sequences. DWI is also helpful for differentiation of
abscess or ischemic lesion. It is essential that radiologists
understand how imaging findings correlate with clinical
features.
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